Physician profile
Daryl C Hacker
NPI 1689652125
$8,771.58
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $1,288 · 2021: $2,105 · 2022: $2,407 · 2023: $875 · 2024: $81.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,427.06 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,400.70 | 2019-2023 | Xifaxan |
| Gilead Sciences, INC. | $729.10 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $591.47 | 2019-2023 | Entyvio |
| Pfizer INC. | $404.43 | 2019-2023 | |
| Celgene Corporation | $344.49 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $317.96 | 2019-2023 | Stelara, Simponi, Simponi Aria |
| Qol Medical, LLC | $280.01 | 2021-2023 | Sucraid |
| Merck Sharp & Dohme LLC | $259.93 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $251.93 | 2019-2022 | |
| Braintree Laboratories, INC. | $232.77 | 2019-2022 | |
| Genzyme Corporation | $184.46 | 2022-2024 | |
| Daiichi Sankyo INC. | $141.16 | 2019-2021 | |
| Evoke Pharma, INC. | $130.53 | 2020-2022 | |
| Redhill Biopharma INC. | $128.87 | 2020-2023 | Aemcolo, Movantik, Talicia |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $120.34 | 2020-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $114.97 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $109.11 | 2022-2023 | Dupixent |
| Micro-Tech Endoscopy USA, INC. | $94.65 | 2019 | |
| Shionogi INC | $77.23 | 2019-2020 | |
| Pharmacosmos Therapeutics INC. | $74.53 | 2020-2022 | |
| Organon LLC | $71.68 | 2022-2023 | Renflexis |
| Shire North American Group INC | $55.86 | 2019 | |
| Amgen INC. | $51.28 | 2021 | |
| Medtronic, INC. | $50.14 | 2021-2023 | Pillcam |
| E.R. Squibb & Sons, L.L.C. | $35.38 | 2022 | |
| Nestle Healthcare Nutrition INC. | $28.99 | 2021 | |
| Sebela Pharmaceuticals INC. | $22.24 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $18.04 | 2024 | Bylvay |
| Alfasigma USA, INC. | $11.24 | 2020 | |
| Allergan, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Hacker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.